Salivary gland non-Hogdgkin's lymphoma (NHL) in patients with Sjogren's syndrome frequently develops from rheumatoid factor B cells. The authors describe a patient with NHL of the parotid glands associated with Sjogren's syndrome whose initial positron emission tomographic (PET) findings included abnormal F-18 fluorodeoxyglucose (FDG) uptake in the parotid glands. After rituximab therapy, a follow-up PET study confirmed a positive response to treatment. This illustrates that F-18 FDG PET can be used to monitor the therapeutic response of NHL parotid glands associated with Sjogren's syndrome.
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
- Fluorine-18 Fluorodeoxyglucose
- Monoclonal Antibody Therapy
- Non-Hodgkin's Lymphoma
- Sjogren's Syndrome